Moreover, the spatially resolved 64Cu-CD4-Nb1-PET data of the TME enables us to forecast treatment resistance, which was further validated through immunofluorescence analysis in both mouse and human NSCLC tumor tissues. This evidence concerns the gene CD4 and non-small cell lung carcinoma.